InsidersTradesSigma
Follow the HLB테라퓨틱스 share price and the full management transaction log of the company, a listed equity based in South Korea. Shares trade on the KR market, under the oversight of DART (FSS). Operating in the Health Care sector, HLB테라퓨틱스 has logged 7 public disclosures. Market capitalisation: €153.4bn. The latest transaction was disclosed on 2 July 2026 (Purchase). Among the most active insiders: HLB. The full history is openly available.
7
Insider Decl.
n/a
Thresholds
€1m
6 ops.
Buy Volume
n/a
n/a
Sell Volume
16Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 27,360 of 29,062 companies
17.0
score / 100
Value19
Quality15
FCF yld-9.8%
Earn yld-5.0%
EV/EBITDA·
ROE-11%
Gross mgn15%
Net mgn-13%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 2 July 2026
Declarations7 total
7 of 7 declarations
关于 HLB테라퓨틱스
HLB Therapeutics 是一家专注于医疗保健和制药领域的公司，在 XKRX 市场上市。它专注于开发创新的治疗方法和治疗解决方案。